77
Participants
Start Date
April 1, 2019
Primary Completion Date
November 18, 2024
Study Completion Date
November 18, 2024
Etrumadenant
Etrumadenant is an A2aR and A2bR antagonist
Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Carboplatin
Carboplatin administered as part of standard chemotherapy regimen
Pemetrexed
Pemetrexed administered as part of standard chemotherapy regimen
Pembrolizumab
Pembrolizumab is a humanized anti-PD-1 monoclonal antibody
Changhua Christian Hospital, Changhua
Seoul National University Hospital, Suwon
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Centre, Seoul
Seoul St. Mary's Hospital, Seoul
National Taiwan University Hospital, Taipei
Tri Service General Hospital, Taipei
Bundang CHA Medical Center, Seongnam-si
The Catholic University of Korea St. Vincent Hospital, Suwon
USO Virginia Cancer Specialist, Fairfax
USO Virginia Oncology Associates, Norfolk
Taipei Medical University - Shuang Ho Hospital, New Taipei City
Chungbuk National University Hospital, Cheongju-si
SCRI Florida Cancer Specialists - North, Tavares
SCRI Florida Cancer Specialists - South, Fort Myers
SCRI Tennessee Oncology - Nashville, Nashville
Chi Mei Hospital, Liouying, Tainan City
USO Texas Oncology - Dallas (Baylor Charles A. Sammons Cancer Center), Dallas
Arizona Cancer Research Center (ACRC), Tucson
Medical Oncology Associates/Summit Cancer Center, Spokane
National University Hospital, Singapore
National Cancer Centre Singapore, Singapore
Lead Sponsor
Collaborators (1)
Gilead Sciences
INDUSTRY
Arcus Biosciences, Inc.
INDUSTRY